At Jubilant Biosys, we provide a comprehensive drug interaction assessment service as part of our integrated DMPK services, essential for scientific research and drug development. Drug interactions occur when one drug affects the activity of another when both are administered together, potentially leading to reduced efficacy or increased toxicity. This proactive approach is vital for minimizing adverse effects and optimizing drug formulations. Our service enhances the efficiency of drug development, reduces the risk of costly late-stage failures, and accelerates time-to-market for new pharmaceuticals. By leveraging our drug interaction checking service, scientists can ensure safer, more effective drug profiles, reinforcing Jubilant Biosys’s commitment to innovation and excellence in the life sciences. We offer our clients an expansive portfolio of DDI services to mitigate this risks in new drugs. These services include various assays for perpetrator and victim DDI assessment - Reversible Cytochrome P450 (CYP) Inhibition – IC50 and Ki - Time Dependent Inhibition CYP Inhibition – IC50 shift - UGT Inhibition – IC50 andKi - CYP Reaction Phenotyping - CytochromeP450 Induction through catalytic activity - Primary hepatocytes (CYP1A2, 2B6, 3A4) - PXR Nuclear Receptor Activation in HepG2 cells (single point, EC50/Emax) - Transporter Inhibition (Efflux and Uptake) –Single point/ IC50 determination - OATP1B1/1B3 - MATE1/2-K - OAT1/3 - OCT2 - Transporter Substrate Identification (Efflux and Uptake) - PgP - BCRP
Compiled from https://www.jubilantbiosys.com
